#ESMO26 SAFFRON: osimertinib + savolitinib improves PFS (HR 0.55) and OS (17.8 vs 12.9 months; HR 0.68) after osimertinib in MET-selected EGFRm NSCLC.

An all-oral option—but how do we choose versus amivantamab + chemotherapy? No head-to-head data. Biology matters.
@myESMO #ESMO26 @Larvol @OncoAlert